Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Avidity Biosciences Inc shares valued at $89,601 were sold by Hughes Steven George on Sep 22 ’25. At $40.58 per share, Hughes Steven George sold 2,208 shares. The insider’s holdings dropped to 38,867 shares worth approximately $1.68 million following the completion of this transaction.
Also, McCarthy Teresa sold 15,000 shares, netting a total of over 621,142 in proceeds. Following the sale of shares at $41.41 each, the insider now holds 97,130 shares.
Before that, Hughes Steven George had sold 1,542 shares from its account. In a trade valued at $70,022, the Chief Medical Officer traded Avidity Biosciences Inc shares for $45.41 each. Upon closing the transaction, the insider’s holdings decreased to 1,542 shares, worth approximately $1.68 million.
As published in their initiating research note from Roth Capital on September 17, 2025, Avidity Biosciences Inc [RNA] has been a Buy and the price target has been revised to $62. As of June 24, 2025, Bernstein has initiated its “an Outperform” rating for RNA. Earlier on June 17, 2025, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for RNA stock.
Analyzing RNA Stock Performance
On last trading session, Avidity Biosciences Inc [NASDAQ: RNA] rose 2.15% to $43.21. The stock’s lowest price that day was $41.84, but it reached a high of $44.5 in the same session. During the last five days, there has been a surge of approximately 7.86%. Over the course of the year, Avidity Biosciences Inc shares have dropped approximately -2.86%. Shares of the company reached a 52-week high of $51.40 on 09/05/25 and a 52-week low of $21.51 on 04/09/25.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
According to the 24-hour chart, there is a support level at 41.87, which, if violated, would cause prices to drop to 40.52. In the upper region, resistance lies at 44.53. The next price resistance is at 45.84. RSI (Relative Strength Index) is 49.65 on the 14-day chart, showing neutral technical sentiment.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp rise in short interest on 2025-08-29 jumping by 1.36 million shares to 17.57 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 16.21 million shares. A jump of 7.74% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.27 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.27.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 65.48% from the previous closing price of $42.3. Analysts anticipate Avidity Biosciences Inc stock to reach 96 by 2025, with the lowest price target being 62. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On June 11, 2025, Raymond James assigned a price target of “a Strong buy” to the stock and initiated coverage with a $65.
